Although the scoring standard and parafibromin antibodies determined the immunohistochemical and predictive sensitivity and specificity of parafibromin expression (Hu et al., 2019), a meta-analysis showed parafibromin loss was found to be more common in PC patients than in those with parathyroid ATA, AD, and hyperplasia. This evidence concerns the gene CDC73 and hyperplasia.